WST vs ATR vs GTLS

For growth investors, West Pharmaceutical Services, Inc.

(WST) is the stronger pick with 6. 3% revenue growth year-over-year, versus 2. 5% for Chart Industries, Inc. (GTLS). AptarGroup, Inc. (ATR) offers the better valuation at 20. 9x trailing P/E (22. 0x forward), making it the more compelling value choice. Analysts rate West Pharmaceutical Services, Inc. (WST) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, AptarGroup, Inc.

(ATR) is the cheapest at 20. 9x versus Chart Industries, Inc. at 629. 6x. On forward P/E, Chart Industries, Inc. is actually cheaper at 16. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: AptarGroup, Inc. wins at 1. 71x versus West Pharmaceutical Services, Inc. 's 4. 38x — a reasonable growth-adjusted valuation.

Over the past 5 years, Chart Industries, Inc.

(GTLS) delivered a total return of +33. 2%, compared to -16. 3% for AptarGroup, Inc. (ATR). Over 10 years, the gap is even starker: GTLS returned +740. 5% versus ATR's +80. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Chart Industries, Inc.

(GTLS) is the lower-risk stock at 0. 56β versus West Pharmaceutical Services, Inc. 's 0. 92β — meaning WST is approximately 65% more volatile than GTLS relative to the S&P 500. On balance sheet safety, West Pharmaceutical Services, Inc. (WST) carries a lower debt/equity ratio of 13% versus 111% for Chart Industries, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), West Pharmaceutical Services, Inc.

(WST) is pulling ahead at 6. 3% versus 2. 5% for Chart Industries, Inc. (GTLS). On earnings-per-share growth, the picture is similar: AptarGroup, Inc. grew EPS 6. 3% year-over-year, compared to -92. 0% for Chart Industries, Inc.. Over a 3-year CAGR, GTLS leads at 38. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

West Pharmaceutical Services, Inc.

(WST) is the more profitable company, earning 16. 1% net margin versus 1. 0% for Chart Industries, Inc. — meaning it keeps 16. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WST leads at 20. 1% versus 13. 6% for ATR. At the gross margin level — before operating expenses — WST leads at 35. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, AptarGroup, Inc. (ATR) is the more undervalued stock at a PEG of 1. 71x versus West Pharmaceutical Services, Inc. 's 4. 38x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Chart Industries, Inc. (GTLS) trades at 16. 4x forward P/E versus 36. 3x for West Pharmaceutical Services, Inc. — 19. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATR: 38. 4% to $169. 67.

All stocks in this comparison pay dividends.

AptarGroup, Inc. (ATR) offers the highest yield at 1. 5%, versus 0. 3% for West Pharmaceutical Services, Inc. (WST).

For long-horizon retirement investors, Chart Industries, Inc.

(GTLS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +740. 5% 10Y return). Both have compounded well over 10 years (GTLS: +740. 5%, WST: +353. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (WST (Healthcare) and ATR (Healthcare) and GTLS (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

ATR pays a dividend while WST, GTLS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.